Breast Cancer Res Treat
Breast Cancer Research and Treatment
0167-6806
1573-7217
Springer US
Boston


2001216
17912633
9696
10.1007/s10549-007-9696-3
Review


The discovery and mechanism of action of letrozole

Bhatnagar
Ajay S.

+41-61-4619974
+41-61-4619984
ajay.bhatnagar@wwsgroup.com



World Wide Services Group Ltd, Geispelgasse 13, CH-4132 Muttenz, Switzerland 

3
10
2007

10
2007

105
Suppl 1
7
17
3
1
2007

17
7
2007


© Springer Science+Business Media, LLC 2007

®
) achieved the goal of discovering a highly potent and totally selective AI. Letrozole has greater potency than other AIs, including anastrozole, exemestane, formestane, and aminoglutethimide. Moreover, letrozole produces near complete inhibition of aromatase in peripheral tissues and is associated with greater suppression of estrogen than is achieved with other AIs. The potent anti-tumor effects of letrozole were demonstrated in several animal models. Studies with MCF-7Ca xenografts successfully predicted that letrozole would be clinically superior to the previous gold standard tamoxifen and also indicated that it may be more effective than other AIs. An extensive program of randomized clinical trials has demonstrated the clinical benefits of letrozole across the spectrum of hormone-responsive breast cancer in postmenopausal women.

Keywords
Aromatase
Breast cancer
Estrogen
Postmenopausal

issue-copyright-statement
© Springer Science+Business Media, LLC. 2007




Introduction
1
2
3
5
6
12
13
14
16
]. These data indicate that estrogen is an important risk factor even in women considered at high risk of developing the disease, for example, those with a family history of breast cancer.
1
3
17
18
19
30
31
32
33
].
34
13
] and are candidates for treatment strategies designed to counteract the growth effects of estrogen. This review describes the rational development of the potent AI letrozole, which has therapeutic utility in HR+ tumors across the breast cancer continuum.

Mechanism of action of aromatase inhibitors
Aromatase
35
37
1
38
39
40
41
42
43
44
1
38
45
49
14
50
53
14
31
Fig. 1
A
E1
E1S
E2
T
38
] with permission from the Society of Endocrinology




41
54
58
41
54
58
59
60
]. Pharmacogenomics may become an increasingly important tool for individualizing hormonal therapy for patients with breast cancer.

Aromatase inhibitors
61
62
63
64
2
65
66
67
68
69
Fig. 2
4-OHA
66
] with permission from the Society of Endocrinology




70
®
71
70
72
73
2
66
74
75
76
].


Letrozole pharmacodynamics and pharmacokinetics
Potency
3
77
70
Fig. 3
77
] with permission from Elsevier




31
4
31
1
31
71
75
78
82
Fig. 4
31
] with permission from Elsevier



Table 1
77
] with permission from Elsevier

Aromatase inhibitor
50
 values (nM), (relative potency; letrozole = 1) 

Human placental microsomes
Particulate fractions of human breast cancer
Rat ovarian microsomes
MCF-7Ca cancer cells
JEG-3 cancer cells
CHO cells
Hamster ovarian tissue
Human breast


Letrozole

2 (1)





0.8 (1)

Anastrozole

8 (0.25)





15 (0.053)

Exemestane

15 (0.13)





5 (0.16)

4-OHA

30 (0.07)





30 (0.027)

AG

20,000 (0.0001)





10,000 (0.0008)

Letrozole
11 (1)


0.07 (1)
0.07 (1)

20 (1)
0.8 (1)

Anastrozole
23 (0.48)


0.82 (0.085)
0.99 (0.071)

600 (0.033)
14 (0.057)

Fadrozole
5 (2.2)


0.05 (1.4)
0.07 (1.0)

30 (0.67)
1 (0.80)

4-OHA
62 (0.18)








AG
1900 (0.0058)








Letrozole
1.02 (1)


0.35 (1.0)
0.45 (1)


0.14 (1)

Anastrozole
5.35 (0.19)


3.62 (0.097)
5.66 (0.080)


17.17 (0.0082)

4-OHA



0.59 (0.59)
1.6 (0.28)


0.72 (0.19)

Letrozole


7 (1)






Anastrozole


25 (0.28)






Fadrozole


7 (1)






Letrozole





1.4 (0)



Anastrozole





27 (0.052)



4-OHA





60 (0.023)



AG





5500 (0.00025)





4-OHA
AG
 aminoglutethimide
50
 values representing the concentration needed to achieve 50% inhibition of aromatase activity. The relative potency of each inhibitor compared with letrozole is shown in parentheses



71
50
71
75
].
83
P
P
P
84
78
85
90
].

Selectivity
77
71
78
71
].
86
91
93
86
].

Anti-tumor activity in vivo
77
78
94
95
50
 for letrozole was determined to be 10–30 μg/kg/day.
61
96
97
94
98
99
99
].
100
100
80
101
101
P
102
102
].
103
104
].

Pharmacokinetics of letrozole
105
107
108
109
1/2
1/2
109
]. The major route of elimination of letrozole is metabolism by CYP-450 isoenzymes (CYP 3A4 and CYP 2A6) into an inactive carbinol metabolite. Systemic exposure to metabolites is, therefore, low. Steady-state concentrations of letrozole are reached after 2–6 weeks and maintained for long periods with no evidence of drug accumulation.
110
1/2
 of letrozole, and caution is required in such patients.
111
]. The clinical significance of such differences is not known.


Clinical development of letrozole
92
112
113
]. Based on pharmacokinetic and pharmacodynamic studies, the recommended dose of letrozole is one 2.5 mg tablet once daily.
97
101
114
118
]. The clinical efficacy of letrozole in advanced breast cancer is described in a review by Dr. Mouridsen in this supplement.
99
102
119
P
120
]. A review by O’Shaughnessy in this supplement provides the rationale for this trial and a description of its design.
121
121
122
]. Full details of this trial are provided in a review by Dr. Goss in this supplement.
123
124
125
].

Conclusions
Letrozole is a highly potent and selective AI that inhibits the enzyme activity of intracellular aromatase at the major sites where it is found, resulting in almost complete suppression of whole body aromatization. By effectively blocking estrogen synthesis, letrozole inhibits the growth or induces the regression of hormone-responsive breast tumors in vivo. Estrogen is implicated as a major risk factor in the majority of breast cancers; therefore, use of the most potent AI is a logical treatment strategy.
118
123
]. Outstanding clinical questions, including what is the most effective AI and what is the optimal sequence for adjuvant hormonal therapy, will be answered by the results of ongoing trials involving letrozole.
In conclusion, experimental data indicating that letrozole efficiently inhibits aromatase activity have been confirmed clinically, leading to approved indications across the spectrum of breast cancer. The broad range of indications for letrozole in unique clinical settings is reshaping the management of hormone-sensitive breast cancer.


References
1.
Yager
JD

Davidson
NE


Estrogen carcinogenesis in breast cancer
N Engl J Med
2006
354
270
282

16421368


2.
Key
TJ

Appleby
PN

Reeves
GK

Roddam
A

Dorgan
JF

Longcope
C

Stanczyk
FZ

Stephenson
HE

Falk
RT

Miller
R

Schatzkin
A

Allen
DS

Fentiman
IS

Key
TJ

Wang
DY

Dowsett
M

Thomas
HV

Hankinson
SE

Toniolo
P

Akhmedkhanov
A

Koenig
K

Shore
RE

Zeleniuch-Jacquotte
A

Berrino
F

Muti
P

Micheli
A

Krogh
V

Sieri
S

Pala
V

Venturelli
E

Secreto
G

Barrett-Connor
E

Laughlin
GA

Kabuto
M

Akiba
S

Stevens
RG

Neriishi
K

Land
CE

Cauley
JA

Kuller
LH

Cummings
SR

Helzlsouer
KJ

Alberg
AJ

Bush
TL

Comstock
GW

Gordon
GB

Miller
SR

Longcope
C

Endogenous Hormones Breast Cancer Collaborative Group

Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
J Natl Cancer Inst
2003
95
1218
1226

12928347


3.
Yue
W

Santen
RJ

Wang
JP

Li
Y

Verderame
MF

Bocchinfuso
WP

Korach
KS

Devanesan
P

Todorovic
R

Rogan
EG

Cavalieri
EL


Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis
J Steroid Biochem Mol Biol
2003
86
477
486

14623547


4.
Clemons
M

Goss
P


Estrogen and the risk of breast cancer
N Engl J Med
2001
344
276
285

11172156


5.
Key
T

Appleby
P

Barnes
I

Reeves
G

Endogenous Hormones, Breast Cancer Collaborative Group

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies
J Natl Cancer Inst
2002
94
606
616

11959894


6.
Collaborative Group on Hormonal Factors in Breast Cancer

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
Lancet
1997
350
1047
1059

10213546


7.
Schairer
C

Lubin
J

Troisi
R

Sturgeon
S

Brinton
L

Hoover
R


Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
JAMA
2000
283
485
491

10659874


8.
Fournier
A

Berrino
F

Riboli
E

Avenel
V

Clavel-Chapelon
F


Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort
Int J Cancer
2005
114
448
454

15551359


9.
Beral
V

Million Women Study Collaborators

Breast cancer and hormone-replacement therapy in the Million Women Study
Lancet
2003
362
419
427

12927427


10.
Rossouw
JE

Anderson
GL

Prentice
RL

LaCroix
AZ

Kooperberg
C

Stefanick
ML

Jackson
RD

Beresford
SA

Howard
BV

Johnson
KC

Kotchen
JM

Ockene

Writing Group for the Women’s Health Initiative Investigators

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial
JAMA
2002
288
321
333

12117397


11.
Anderson
GL

Limacher
M

Assaf
AR

Bassford
T

Beresford
SA

Black
H

Bonds
D

Brunner
R

Brzyski
R

Caan
B

Chlebowski
R

Curb
D

Gass
M

Hays
J

Heiss
G

Hendrix
S

Howard
BV

Hsia
J

Hubbell
A

Jackson
R

Johnson
KC

Judd
H

Kotchen
JM

Kuller
L

LaCroix
AZ

Lane
D

Langer
RD

Lasser
N

Lewis
CE

Manson
J

Margolis
K

Ockene
J

O’Sullivan
MJ

Phillips
L

Prentice
RL

Ritenbaugh
C

Robbins
J

Rossouw
JE

Sarto
G

Stefanick
ML

Horn
L

Wactawski-Wende
J

Wallace
R

Wassertheil-Smoller
S

Women’s Health Initiative Steering Committee

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial
JAMA
2004
291
1701
1712

15082697


12.
Collaborative Group on Hormonal Factors in Breast Cancer

Breast cancer and hormonal contraceptives: further results
Contraception
1996
54
Suppl 3
1S
106S

8899264


13.
Huang
WY

Newman
B

Millikan
RC

Schell
MJ

Hulka
BS

Moorman
PG


Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status
Am J Epidemiol
2000
151
703
714

10752798


14.
Miller
WR

Forrest
AP


Oestradiol synthesis by a human breast carcinoma
Lancet
1974
2
866
868

4137868


15.
Miller
WR

Telford
J

Dixon
JM

Hawkins
RA


Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity
Eur J Cancer Clin Oncol
1985
21
539
542

4007019


16.
Miller
WR

O’Neill
J


The importance of local synthesis of estrogen within the breast
Steroids
1987
50
537
548

3504615


17.
Devanesan
P

Santen
RJ

Bocchinfuso
WP

Korach
KS

Rogan
EG

Cavalieri
E


Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors
Carcinogenesis
2001
22
1573
1576

11532882


18.
Cavalieri
EL

Stack
DE

Devanesan
PD

Todorovic
R

Dwivedy
I

Higginbotham
S

Johansson
SL

Patil
KD

Gross
ML

Gooden
JK

Ramanathan
R

Cerny
RL

Rogan
EG


Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators
Proc Natl Acad Sci USA
1997
94
10937
10942

9380738


19.
Santen
RJ

Lobenhofer
EK

Afshari
CA

Bao
Y

Song
RX


Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells
Breast Cancer Res Treat
2005
94
213
223

16258703


20.
Webb
P

Nguyen
P

Valentine
C

Lopez
GN

Kwok
GR

McInerney
E

Katzenellenbogen
BS

Enmark
E

Gustafsson
JA

Nilsson
S

Kushner
PJ


The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
Mol Endocrinol
1999
13
1672
1685

10517669


21.
Sabbah
M

Courilleau
D

Mester
J

Redeuilh
G


Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element
Proc Natl Acad Sci USA
1999
96
11217
11222

10500157


22.
Levin
ER


Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor
Mol Endocrinol
2003
17
309
317

12554774


23.
Stoica
GE

Franke
TF

Moroni
M

Mueller
S

Morgan
E

Iann
MC

Winder
AD

Reiter
R

Wellstein
A

Martin
MB

Stoica
A


Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway
Oncogene
2003
22
7998
8011

12970748


24.
Sekeris
CE


The mitochondrial genome: a possible primary site of action of steroid hormones
In vivo
1990
4
317
320

2133104


25.
Liao
JK


Cross-coupling between the oestrogen receptor and phosphoinositide 3-kinase
Biochem Soc Trans
2003
31
66
70

12546655


26.
Aronica
SM

Kraus
WL

Katzenellenbogen
BS


Estrogen action via the cAMP signalling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription
Proc Natl Acad Sci USA
1994
91
8517
8521

8078914


27.
Migliaccio
A

Di Domenico
M

Castoria
G

Falco
A

Bontempo
P

Nola
E

Auricchio
F


Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
EMBO J
1996
15
1292
1300

8635462


28.
Song
RX-D

McPherson
RA

Adam
L

Bao
Y

Shupnik
M

Kumar
R

Santen
RJ


Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation
Mol Endocrinol
2002
16
116
127

11773443


29.
Razandi
M

Pedram
A

Greene
GL

Levin
ER


Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells
Mol Endocrinol
1999
13
307
319

9973260


30.
Razandi
M

Pedram
A

Levin
ER


Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer
Mol Endocrinol
2000
14
1434
1447

10976921


31.
Bhatnagar
AS

Brodie
AMH

Long
BJ

Evans
DB

Miller
WR


Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors
J Steroid Biochem Mol Biol
2001
76
199
202

11384878


32.
Osborne
CK

Coronado-Heinsohn
EB

Hilsenbeck
SG

McCue
BL

Wakeling
AE

McClelland
RA

Manning
DL

Nicholson
RI


Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
J Natl Cancer Inst
1995
87
746
750

7563152


33.
Gutierrez
MC

Detre
S

Johnston
S

Mohsin
SK

Shou
J

Allred
DC

Schiff
R

Osborne
CK

Dowsett
M


Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
J Clin Oncol
2005
23
2469
2476

15753463


34.
Goldhirsch
A

Glick
JH

Gelber
RD

Coates
AS

Thurlimann
B

Senn
HJ

Panel members

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
Ann Oncol
2005
16
1569
1583

16148022


35.
Ryan
KJ


Biological aromatization of steroids
J Biol Chem
1959
234
268
272

13630892


36.
Meigs
RA

Ryan
KJ


Cytochrome P-450 and steroid biosynthesis in the human placenta
Biochim Biophys Acta
1968
165
476
482

Meigs RA, Ryan KJ (1968) Cytochrome P-450 and steroid biosynthesis in the human placenta. Biochim Biophys Acta 165:476–482 

37.
Fishman
J

Raju
MS


Mechanism of estrogen biosynthesis. Stereochemistry of C-1 hydrogen elimination in the aromatization of 2 beta-hydroxy-19-oxoandrostenedione
J Biol Chem
1981
256
4472
4477

7012154


38.
Lønning
PE


Aromatase inhibitors in breast cancer
Endocr Relat Cancer
2004
11
179
189

15163297


39.
Brodie
AM

Schwarzel
WC

Shaikh
AA

Brodie
HJ


The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer
Endocrinology
1977
100
1684
1695

404132


40.
Brodie
AM

Brodie
HJ

Garrett
WM

Hendrickson
JR

Marsh
DA

Tsai-Morris
CH


Effect of an aromatase inhibitor, 1,4,6-androstatriene-3,17-dione, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat and its mechanism of action in vivo
Biochem Pharmacol
1982
31
2017
2023

6810900


41.
Longcope
C

Pratt
JH

Schneider
SH

Fineberg
SE


Aromatization of androgens by muscle and adipose tissue in vivo
J Clin Endocrinol Metab
1978
46
146
152

752017


42.
Miller
WR


Aromatase activity in breast tissue
J Steroid Biochem Mol Biol
1991
39
783
790

1954167


43.
Couzinet
B

Meduri
G

Lecce
MG

Young
J

Brailly
S

Loosfelt
H

Milgrom
E

Schaison
G


The postmenopausal ovary is not a major androgen-producing gland
J Clin Endocrinol Metab
2001
86
5060
5066

11600585


44.
Hemsell
DL

Grodin
JM

Brenner
PF

Siiteri
PK

MacDonald
PC


Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age
J Clin Endocrinol Metab
1974
38
476
479

4815174


45.
Schweikert
HU

Milewich
L

Wilson
JD


Aromatization of androstenedione by cultured human fibroblasts
J Clin Endocrinol Metab
1976
43
785
795

977721


46.
Smuk
M

Schwers
J


Aromatization of androstenedione by human adult liver in vitro
J Clin Endocrinol Metab
1977
45
1009
1012

925126


47.
Perel
E

Killinger
DW


The interconversion and aromatization of androgens by human adipose tissue
J Steroid Biochem
1979
10
623
627

470385


48.
Frisch
RE

Canick
JA

Tulchinsky
D


Human fatty marrow aromatizes androgen to estrogen
J Clin Endocrinol Metab
1980
51
394
396

7400303


49.
Matsumine
H

Hirato
K

Yanaihara
T

Tamada
T

Yoshida
M


Aromatization by skeletal muscle
J Clin Endocrinol Metab
1986
63
717
720

3734038


50.
Perel
E

Wilkins
D

Killinger
DW


The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue
J Steroid Biochem
1980
13
89
94

7382486


51.
Reed
MJ

Owen
AM

Lai
LC

Coldham
NG

Ghilchik
MW

Shaikh
NA

James
VH


In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione
Int J Cancer
1989
44
233
237

2759729


52.
Miller
WR

Anderson
TJ

Jack
WJ


Relationship between tumour aromatase activity, tumour characteristics and response to therapy
J Steroid Biochem Mol Biol
1990
37
1055
1059

2285581


53.
Bulun
SE

Price
TM

Aitken
J

Mahendroo
MS

Simpson
ER


A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
J Clin Endocrinol Metab
1993
77
1622
1628

8117355


54.
Edery
M

Goussard
J

Dehennin
L

Scholler
R

Reiffsteck
J

Drosdowsky
MA


Endogenous oestradiol-17beta concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content
Eur J Cancer
1981
17
115
120

7262142


55.
Miller
WR

Hawkins
RA

Forrest
AP


Steroid metabolism and oestrogen receptors in human breast carcinomas
Eur J Cancer Clin Oncol
1981
17
913
917

7198979


56.
Landeghem
AAI

Poortman
J

Nabuurs
M

Thijssen
JHH


Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue
Cancer Res
1985
45
2900
2906

3986816


57.
Vermeulen
A

Deslypere
JP

Paridaens
R

Leclercq
G

Roy
F

Heuson
JC


Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
Eur J Cancer Clin Oncol
1986
22
515
525

3015631


58.
Geisler
J

Detre
S

Berntsen
H

Ottestad
L

Lindtjørn
B

Dowsett
M

Lønning
PE


Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer
Clin Cancer Res
2001
7
1230
1236

11350888


59.
Bulun
SE

Lin
Z

Imir
G

Amin
S

Demura
M

Yilmaz
B

Martin
R

Utsunomiya
H

Thung
S

Gurates
B

Tamura
M

Langoi
D

Deb
S


Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment
Pharmacol Rev
2005
57
359
383

16109840


60.
Ma
CX

Adjei
AA

Salavaggione
OE

Coronel
J

Pelleymounter
L

Wang
L

Eckloff
BW

Schaid
D

Wieben
ED

Adjei
AA

Weinshilboum
RM


Human aromatase: gene resequencing and functional genomics
Cancer Res
2005
65
11071
11082

16322257


61.
Swain
SM


Aromatase inhibitors—a triumph of translational oncology
N Engl J Med
2005
353
2807
2809

16382068


62.
Santen
RJ

Santner
S

Davis
B

Veldhuis
J

Samojlik
E

Ruby
E


Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
J Clin Endocrinol Metab
1978
47
1257
1265

263348


63.
Hausler
A

Schenkel
L

Krahenbuhl
C

Monnet
G

Bhatnagar
AS


An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors
J Steroid Biochem
1989
33
125
131

2527324


64.
Pittman
JA

Brown
RW


Antithyroid and antiadrenocortical activity of aminoglutethimide
J Clin Endocrinol Metab
1966
26
1014
1016

4162763


65.
Murray
M

Cantrill
E

Farrell
GC


Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide
J Pharmacol Exp Ther
1993
265
477
481

8474030


66.
Santen
RJ

Harvey
HA


Use of aromatase inhibitors in breast carcinoma
Endocr Relat Cancer
1999
6
75
92

10732791


67.
Santen
RJ

Demers
LM

Lynch
J

Harvey
H

Lipton
A

Mulagha
M

Hanagan
J

Garber
JE

Henderson
IC

Navari
RM

Miller
AA


Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor
J Clin Endocrinol Metab
1991
73
99
106

1646219


68.
Falkson
CI

Falkson
HC


A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer
Ann Oncol
1996
7
465
469

8839900


69.
Thürlimann
B

Beretta
K

Bacchi
M

Castiglione-Gertsch
M

Goldhirsch
A

Jungi
WF

Cavalli
F

Senn
H-J

Fey
M

Löhnert
T


First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Ann Oncol
1996
7
471
479

8839901


70.
Lang
M

Batzl
C

Furet
P

Bowman
R

Häusler
A

Bhatnagar
AS


Structure-activity relationships and binding model of novel aromatase inhibitors
J Steroid Biochem Mol Biol
1993
44
421
428

8476755


71.
Bhatnagar
AS

Häusler
A

Schieweck
K

Lang
M

Bowman
R


Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
J Steroid Biochem Mol Biol
1990
37
1021
1027

2149502


72.
Furet
P

Batzl
C

Bhatnagar
A

Francotte
E

Rihs
G

Lang
M


Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds
J Med Chem
1993
36
1393
1400

8496907


73.
Plourde
PV

Dyroff
M

Dukes
M


Arimidex: a potent and selective fourth-generation aromatase inhibitor
Breast Cancer Res Treat
1994
30
103
111

7949201


74.
Giudici
D

Ornati
G

Briatico
G

Buzzetti
F

Lombardi
P

di Salle
E


6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor
J Steroid Biochem
1988
30
391
394

3386266


75.
Miller
WR


Biology of aromatase inhibitors: pharmacology/endocrinology within the breast
Endocr Relat Cancer
1999
6
187
195

10731108


76.
Njar
VC

Brodie
AM


Comprehensive pharmacology and clinical efficacy of aromatase inhibitors
Drugs
1999
58
233
255

10473018


77.
Haynes
BP

Dowsett
M

Miller
WR

Dixon
JM

Bhatnagar
AS


The pharmacology of letrozole
J Steroid Biochem Mol Biol
2003
87
35
45

14630089


78.
Bhatnagar
AS

Batzl
C

Hausler
A

Schieweck
K

Lang
M

Trunet
PF


Pasqualini


Pharmacology of non-steroidal aromatase inhibitors
Hormone-dependent cancer
1996
New York
Marcel Dekker
155
168

Bhatnagar AS, Batzl C, Hausler A, Schieweck K, Lang M, Trunet PF (1996) Pharmacology of non-steroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone-dependent cancer. Marcel Dekker, New York, pp 155–168 

79.
Long
BJ

Tilghman
SL

Yue
W

Thiantanawat
A

Grigoryev
DN

Brodie
AM


The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity
J Steroid Biochem Mol Biol
1998
67
293
304

9883986


80.
Lu
Q

Liu
Y

Long
BJ

Grigoryev
D

Gimbel
M

Brodie
A


The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer
Breast Cancer Res Treat
1999
57
183
192

10598045


81.
Odum
J

Ashby
J


Detection of aromatase inhibitors in vitro using rat ovary microsomes
Toxicol Lett
2002
129
119
122

11879982


82.
Kao
YC

Cam
LL

Laughton
CA

Zhou
D

Chen
S


Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study
Cancer Res
1996
56
3451
3460

8758911


83.
Geisler
J

Haynes
B

Anker
G

Dowsett
M

Lønning
PE


Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
J Clin Oncol
2002
20
751
757

11821457


84.
Dixon
JM

Renshaw
L

Young
O

Murray
J

Macaskill
EJ

McHugh
M

Folkerd
E

Cameron
D

Dowsett
M


Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer [abstract]
J Clin Oncol
2006
24
Suppl 18
552

16391300


85.
Demers
LM

Lipton
A

Harvey
HA

Kambic
KB

Grossberg
H

Brady
C

Santen
RJ


The efficacy of CGS 20267 in suppressing estrogen biosynthesis in women with advanced stage breast cancer
J Steroid Biochem Mol Biol
1993
44
687
691

8476785


86.
Demers
LM


Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
Breast Cancer Res Treat
1994
30
95
102

7949208


87.
Dowsett
M

Jones
A

Johnston
SRD

Jacobs
S

Trunet
P

Smith
IE


In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
Clin Cancer Res
1995
1
1511
1515

9815951


88.
Geisler
J

King
N

Dowsett
M

Ottestad
L

Lundgren
S

Walton
P

Kormeset
PO

Lønning
PE


Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
Br J Cancer
1996
74
1286
1291

8883419


89.
Geisler
J

King
N

Anker
G

Ornati
G

Di Salle
E

Lønning
PE

Dowsett
M


In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
Clin Cancer Res
1998
4
2089
2093

9748124


90.
Bernardi
A

Zamagni
C

Di Fabio
F

Piana
E

Martoni
A

Vecchi
F


Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer [abstract]
Proc Am Soc Clin Oncol
2002
21
217

Bernardi A, Zamagni C, Di Fabio F, Piana E, Martoni A, Vecchi F (2002) Randomized comparative study on estrogen suppression induced by 3 different aromatase inhibitors in postmenopausal patients with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 21:217 

91.
Iveson
TJ

Smith
IE

Ahern
J

Smithers
DA

Trunet
PF

Dowsett
M


Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women
J Clin Endocrinol Metab
1993
77
324
331

8345035


92.
Iveson
TJ

Smith
IE

Ahern
J

Smithers
DA

Trunet
PF

Dowsett
M


Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer
Cancer Res
1993
53
266
270

8417819


93.
Bajetta
E

Zilembo
N

Dowsett
M

Guillevin
L

Di Leo
A

Celio
L

Martinetti
A

Marchiano
A

Pozzi
P

Stani
S

Bichisao
E


Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
Eur J Cancer
1999
35
208
213

10448261


94.
Brodie
A

Lu
Q

Liu
Y

Long
B


Aromatase inhibitors and their antitumor effects in model systems
Endocr Relat Cancer
1999
6
205
210

10731110


95.
Schieweck
K

Bhatnagar
AS

Batzl
C

Lang
M


Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors
J Steroid Biochem Mol Biol
1993
44
633
636

8476774


96.
Yue
W

Brodie
A


MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors
J Steroid Biochem Mol Biol
1993
44
671
673

8476781


97.
Yue
W

Zhou
D

Chen
S

Brodie
A


A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene
Cancer Res
1994
54
5092
5095

7923123


98.
Jelovac
D

Macedo
L

Goloubeva
OG

Handratta
V

Brodie
AMH


Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
Cancer Res
2005
65
5439
5444

15958593


99.
Lu
Q

Yue
W

Wang
J

Liu
Y

Long
B

Brodie
A


The effects of aromatase inhibitors and antiestrogens in the nude mouse model
Breast Cancer Res Treat
1998
50
63
71

9802621


100.
Yue
W

Wang
J

Savinov
A

Brodie
A


Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model
Cancer Res
1995
55
3073
3077

7606729


101.
Long
BJ

Jelovac
D

Handratta
V

Thiantanawat
A

MacPherson
N

Ragaz
J

Goloubeva
OG

Brodie
AM


Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model
J Natl Cancer Inst
2004
96
456
465

15026471


102.
Jelovac
D

Macedo
L

Handratta
V

Long
BJ

Goloubeva
OG

Ingle
JN

Brodie
AMH


Effects of exemestane and tamoxifen in a postmenopausal breast cancer model
Clin Cancer Res
2004
10
7375
7381

15534114


103.
Tekmal
RR

Kirma
N

Gill
K

Fowler
K


Aromatase overexpression and breast hyperplasia, an in vivo model—continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands
Endocr Relat Cancer
1999
6
307
314

10731124


104.
Markovits
JE

Sahota
PS


Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats
Toxicol Pathol
2000
28
799
801

11127293


105.
Sioufi
A

Gauducheau
N

Pineau
V

Marfil
F

Jaouen
A

Cardot
JM

Godbillon
J

Czendlik
C

Howald
H

Pfister
C

Vreeland
F


Absolute bioavailability of letrozole in healthy postmenopausal women
Biopharm Drug Dispos
1997
18
779
789

9429742


106.
Sioufi
A

Sandrenan
N

Godbillon
J

Trunet
P

Czendlik
C

Howald
H

Pfister
C

Ezzet
F


Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration
Biopharm Drug Dispos
1997
18
489
497

9267682


107.
Colussi
DM

Parisot
CY

Lefèvre
GY


Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor
J Clin Pharmacol
1998
38
727
735

9725549


108.
Dowsett
M

Pfister
C

Johnston
SRD

Miles
DW

Houston
SJ

Verbeek
JA

Gundacker
H

Sioufi
A

Smith
IE


Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
Clin Cancer Res
1999
5
2338
2343

10499602


109.
Pfister
CU

Martoni
A

Zamagni
C

Lelli
G

Braud
F

Souppart
C

Duval
M

Hornberger
U


®
) in breast cancer patients
Biopharm Drug Dispos
2001
22
191
197

11745921


110.
Dowsett
M

Pfister
CU

Johnston
SRD

Houston
SJ

Miles
DW

Verbeek
JA

Smith
IE


Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer
The Breast
1997
6
245

Dowsett M, Pfister CU, Johnston SRD, Houston SJ, Miles DW, Verbeek JA, Smith IE (1997) Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer. The Breast 6:245 

111.
Lønning
P

Pfister
C

Martoni
A

Zamagni
C


Pharmacokinetics of third-generation aromatase inhibitors
Semin Oncol
2003
30
Suppl 14
23
32

14513434


112.
Femara prescribing information (2005) Novartis

113.
Trunet
PF

Mueller
P

Bhatnagar
AS

Dickes
I

Monnet
G

White
G


Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects
J Clin Endocrinol Metab
1993
77
319
323

8345034


114.
Buzdar
A

Douma
J

Davidson
N

Elledge
R

Morgan
M

Smith
R

Porter
L

Nabholtz
J

Xiang
X

Brady
C


Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
J Clin Oncol
2001
19
3357
3366

11454883


115.
Dombernowsky
P

Smith
I

Falkson
G

Leonard
R

Panasci
L

Bellmunt
J

Bezwoda
W

Gardin
G

Gudgeon
A

Morgan
M

Fornasiero
A

Hoffmann
W

Michel
J

Hatschek
T

Tjabbes
T

Chaudri
HA

Hornberger
U

Trunet
PF


Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
J Clin Oncol
1998
16
453
461

9469328


116.
Gershanovich
M

Chaudri
HA

Campos
D

Lurie
H

Bonaventura
A

Jeffrey
M

Buzzi
F

Bodrogi
I

Ludwig
H

Reichardt
P

O’Higgins
N

Romieu
G

Friederich
P

Lassus
M

for the Letrozole International Trial Group (AR/BC3)

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
Ann Oncol
1998
9
639
645

9681078


117.
Mouridsen
H

Gershanovich
M

Sun
Y

Pérez-Carrión
R

Boni
C

Monnier
A

Apffelstaedt
J

Smith
R

Sleeboom
HP

Janicke
F

Pluzanska
A

Dank
M

Becquart
D

Bapsy
PP

Salminen
E

Snyder
R

Lassus
M

Verbeek
JA

Staffler
B

Chaudri-Ross
HA

Dugan
M


Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group
J Clin Oncol
2001
19
2596
2606

11352951


118.
Mouridsen
H

Gershanovich
M

Sun
Y

Pérez-Carrión
R

Boni
C

Monnier
A

Apffelstaedt
J

Smith
R

Sleeboom
HP

Jaenicke
F

Pluzanska
A

Dank
M

Becquart
D

Bapsy
PP

Salminen
E

Snyder
R

Chaudri-Ross
H

Lang
R

Wyld
P

Bhatnagar
A


Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
J Clin Oncol
2003
21
2101
2109

12775735


119.
Rose
C

Vtoraya
O

Pluzanska
A

Davidson
N

Gershanovich
M

Thomas
R

Johnson
S

Caicedo
JJ

Gervasio
H

Manikhas
G

Ben Ayed
F

Burdette-Radoux
S

Chaudri-Ross
HA

Lang
R


An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
Eur J Cancer
2003
39
2318
2327

14556923


120.
DeBoer R, Burris H, Monnier A, Mouridsen H, O’Shaughnessy J, McIntyre K, Pritchard K, Smith I, Yardley D, on behalf of the H2H trial steering committee (2006) The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer [abstract]. J Clin Oncol 24(18S):582s. Abstract 10672

121.
Goss
PE

Ingle
JN

Martino
S

Robert
NJ

Muss
HB

Piccart
MJ

Castiglione
M

Tu
D

Shepherd
LE

Pritchard
KI

Livingston
RB

Davidson
NE

Norton
L

Perez
EA

Abrams
JS

Therasse
P

Palmer
MJ

Pater
JL


A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
N Eng J Med
2003
349
1793
1802

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Eng J Med 349:1793–1802 

122.
Goss
PE

Ingle
JN

Martino
S

Robert
NJ

Muss
HB

Piccart
MJ

Castiglione
M

Tu
D

Shepherd
LE

Pritchard
KI

Livingston
RB

Davidson
NE

Norton
L

Perez
EA

Abrams
JS

Cameron
DA

Palmer
MJ

Pater
JL


Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
J Natl Cancer Inst
2005
97
1262
1271

16145047


123.
Thürlimann
B

Keshaviah
A

Coates
AS

Mouridsen
H

Mauriac
L

Forbes
JF

Paridaens
R

Castiglione-Gertsch
M

Gelber
RD

Rabaglio
M

Smith
I

Wardly
A

Price
KN

Goldhirsch
A

Breast International Group (BIG) 1-98 Collaborative Group

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
N Engl J Med
2005
353
2747
2757

16382061


124.
Ellis
MJ

Coop
A

Singh
B

Mauriac
L

Llombert-Cussac
A

Jänicke
F

Miller
WR

Evans
DB

Dugan
M

Brady
C

Quebe-Fehling
E

Borgs
M


Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial
J Clin Oncol
2001
19
3808
3816

11559718


125.
Dowsett
M

A’Hern
R

Smith
I

on behalf of the IMPACT Trialists

Ki67 after 2 weeks endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial [abstract]
Breast Cancer Res Treat
2005
94
Suppl 1
45

Dowsett M, A’Hern R, Smith I; on behalf of the IMPACT Trialists (2005) Ki67 after 2 weeks endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial [abstract]. Breast Cancer Res Treat 94(Suppl 1):45 


http://dx.doi.org/10.1007/s10549-007-9857-4





